Market Research Future (MRFR) believes that the autoimmune disease diagnostics market can account for USD 6.75 Billion by 2027-end. The anticipated growth rate of the market size will be 8.4% from 2020 to 2027.
Escalating burden of diseases and conditions including Hashimoto’s thyroiditis, and rheumatoid arthritis, along with the rise in supportive government regulations will have a significant influence over the autoimmune disease diagnostics industry. The American Autoimmune Related Diseases Association reveals that close to 60 million Americans at present suffer from some or the other autoimmune related disorders. These numbers will be escalating over the analysis period. The huge demand for precise and better diagnostic methods, and the heightened cases will enhance the market share in the years to come.
However, the long waiting period pertaining to the diagnostic tests results and the shortage of skilled and experienced healthcare professionals in emerging countries could deter the business growth to some extent.
Having said that, the surge in extensive research and development activities backed by the government bodies aimed at making technically sophisticated diagnosis methods will ensure considerable business expansion.
The autoimmune disease diagnostics market has been segmented on the basis of disease type, test type, and end-user.
On the basis of disease type, the market has been classified as systemic autoimmune disease, and localized autoimmune disease. The systemic autoimmune disease segment has been further divided into psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), and others. Localized autoimmune disease segment has been classified into inflammatory bowel disease, thyroid, type 1 diabetes, and others.
The test type segment has been divided into western blotting, enzyme-linked immunosorbent assay (ELISA), double immune diffusion, dot blot, counter immune-electrophoresis, line blot, immunofluorescence assays (IFA), multiplex immunoassay, agglutination, and others.
The market, by end-user, has been segmented into hospitals, diagnostics centers, research laboratories, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The autoimmune disease diagnostics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European autoimmune disease diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The autoimmune disease diagnostics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Autoimmune Disease Diagnostics market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary:
The Americas are expected to hold the maximum share of global autoimmune disease diagnostics market owing to the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, increasing financial support by government and private organizations, and adoption of highly advanced technology. According to the report published by Arthritis Foundation in 2017, arthritis is serious problem in United states, approximately 91 million Americans were suffering from arthritis, out of which 300000 were children.
Autoimmune Disease Diagnostics Global Market Share, by Region , 2017 (%)
Source: MRFR Analysis
The European market is likely to be the second-largest autoimmune disease diagnostics market. The market growth in this region can be attributed to the increasing automation in laboratories, growing healthcare industry, and aggressive strategies implemented by major players in the region. For instance, in November 2018, bioMérieux SA bought majority shares in Suzhou Hybiome Biomedical Engineering Co. Ltd, with this deal the company will strengthen its position in autoimmune disease diagnostics market and also help the help to enter into the Chinese market.
Asia-Pacific is expected to be the fastest-growing autoimmune disease diagnostics market during the forecast period owing to the rising population, increasing prevalence of autoimmune disorders, and increasing private-public partnerships for improvement of healthcare sector. According to the Arthritis Foundation of Asia, 47 percent of adults with diabetes and 49 percent heart patients are suffering from arthritis, this percentage in likely to increase in the future and burden of autoimmune diseases will cost a fortune to the healthcare sector.
The market in the Middle East & Africa is expected to hold the smallest share of the autoimmune disease diagnostics global market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Sri Ramakrishna Hospital, collaborates with NeuroEquilibrium to launch the first-ever super-speciality vertigo and dizziness diagnosis & treatment center in Coimbatore. The center will have advanced vertigo diagnostic equipment and offer specialized rehabilitation therapies to patients suffering from balance disorders. To understand the source of Vertigo among the patients, tests are conducted with the use of diagnostic devices including Electronystagmography (ENG), Videonystagmography (VNG), Subjective Visual Vertical (SVV), Craniocorpography (CCG), Vestibular Rehabilitation Therapy (VRT), and computerized Dynamic Visual Acuity (DVA).
Oxford BioDynamics Plc, a biotechnology firm creating precision medicine testing methods for immune health, which is based on the company’s EpiSwitch 3D genomics platform, has successfully launched its Checkpoint Inhibitor Response Test (EpiSwitch CiRT). The first-of-its-kind diagnostic blood helps detect the chances of cancer patient’s response rate to Immune Checkpoint Inhibitors (ICIs), such as anti-PD-L1 and anti-PD-1 immunotherapies.
Autoimmune Disease Diagnostics Market By Disease Type
Autoimmune Disease Diagnostics Market By Test Type
Autoimmune Disease Diagnostics Market By End-User
Autoimmune Disease Diagnostics Market By Region
|Market Size||2027: USD 6.75 Billion|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Disease Type, Test Type, And End-User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Siemens Healthcare Private Limited, bioMérieux SA, Bio-rad Laboratories, Beckman Coulter, Inc., AstraZeneca, EUROIMMUN AG, F. Hoffmann-la Roche, Inova Diagnostics, Inc.,Myriad Genetics, Inc., Thermo Fisher Scientific, Trinity Biotech Plc., and Hemagen Diagnostics, Inc.|
|Key Market Opportunities||Advances 3D Printing technologies and applications|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Common autoimmune disorders include:Multiple sclerosis, Myasthenia gravis, Pernicious anemia, Reactive arthritis, Rheumatoid arthritis, Sjögren syndrome, Systemic lupus erythematosus, Type I diabetes.
The test type segment has been divided into Western Blotting, Enzyme-linked Immunosorbent Assay (ELISA), Double Immune Diffusion, Dot Blot, Counter Immune-electrophoresis, Line Blot, Immunofluorescence assays (IFA), Multiplex Immunoassay, Agglutination
The Americas is projected to command the largest share in the autoimmune disease diagnostics market.
Increasing healthcare expenditure and rising prevalence of autoimmune diseases are boosting market growth.
Price war may limit market growth.
The autoimmune disease diagnostics market is projected to grow at a 8.4% CAGR between 2020-2027
The autoimmune disease diagnostics market is predicted to touch USD 6.75 Billion by 2027.